<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>CEFUROXIME AXETILÂ - cefuroxime axetilÂ tabletÂ </strong><br>Physicians Total Care, Inc.<br></p></div>
<h1></h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1"></a><p></p>
<a href="http://"></a>Rx Only<br>To reduce the development of 
drug-resistant bacteria and maintain the effectiveness of cefuroxime axetil and 
other antibacterial drugs, cefuroxime axetil should be used only to treat or 
prevent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused by 
bacteria.<a href="http://"></a>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Cefuroxime axetil tablets contain cefuroxime as cefuroxime axetil. Cefuroxime 
axetil is a semisynthetic, broad-spectrum cephalosporin antibiotic for oral 
administration.<br>Â <br>Chemically, cefuroxime axetil, the 1-(acetyloxy) ethyl 
ester of cefuroxime, is (<span class="Italics">RS </span>)-1-hydroxyethyl (6<span class="Italics">R</span>,7<span class="Italics">R</span>)-7-[2-(2-furyl)glyoxyl-amido]-3-(hydroxymethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]-oct-2-ene-2-carboxylate, 
7<span class="Sup">2</span>-(<span class="Italics">Z</span>)-(<span class="Italics">O</span>-methyl-oxime), 1-acetate 3-carbamate. Its molecular 
formula is C<span class="Sub">20</span>H<span class="Sub">22</span>N<span class="Sub">4</span>O<span class="Sub">10</span>S, and it has a molecular weight of 
510.48.<br>Â <br>Cefuroxime axetil is in the amorphous form and has the following 
structural formula:</p>
<p><img alt="image of chemical structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=61d3f51b-a8ed-4be5-849c-4bf653538d3e&amp;name=chemical%20structure.jpg"><br></p>
<p>Cefuroxime axetil tablets are uncoated and contain the equivalent of 125, 250 or 
500 mg of cefuroxime as cefuroxime axetil. Cefuroxime axetil tablets contain the 
inactive ingredients colloidal silicon dioxide, croscarmellose sodium, 
hydrogenated vegetable oil, microcrystalline cellulose and sodium lauryl 
sulfate<span class="Bold">.</span><a href="http://"></a></p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First"><span class="Bold">Absorption and Metabolism: </span>After oral administration, 
cefuroxime axetil is absorbed from the gastrointestinal tract and rapidly 
hydrolyzed by nonspecific esterases in the intestinal mucosa and blood to 
cefuroxime. Cefuroxime is subsequently distributed throughout the extracellular 
fluids. The axetil moiety is metabolized to acetaldehyde and acetic 
acid.<br><br><span class="Bold">Pharmacokinetics: </span>Approximately 50%of serum 
cefuroxime is bound to protein. Serum pharmacokinetic parameters for cefuroxime 
axetil tablets are shown in Table 1.Â <br></p>
<a name="i09b9b6f8-5ea1-47ad-837c-c7bed7a58da4"></a><table border="0" cellpadding="0" cellspacing="0">
<caption><span>Table 1. Postprandial Pharmacokinetics of Cefuroxime Administered 
asÂ Cefuroxime Axetil Tablets to Adults* </span></caption>
<tbody class="Headless">
<tr class="First">
<td>
<br>Dose<span class="Sup">â€ </span><br>(Cefuroxime<br>Equivalent)Â  </td>
<td>
<br>Peak Plasma<br>Concentration<br>(mcg/mL) </td>
<td>
<br>Time of Peak<br>Plasma 
<br>Concentration (hr) <br>
</td>
<td>
<br>Â Â  Mean<br>Â Elimination<br>Half-Life (hr) </td>
<td>
<br>Â Â Â  AUC<br>(mcg-hr mL) </td>
</tr>
<tr>
<td>
<br>Â Â Â 125 mg <br>
</td>
<td>
<br>2.1<br>
</td>
<td>
<br>2.2<br>
</td>
<td>
<br>1.2<br>
</td>
<td>
<br>6.7<br>
</td>
</tr>
<tr>
<td>
<br>Â Â Â 250 mg <br>
</td>
<td>
<br>4.1<br>
</td>
<td>
<br>2.5<br>
</td>
<td>
<br>1.2<br>
</td>
<td>
<br>12.9<br>
</td>
</tr>
<tr>
<td>
<br>Â Â Â 500 mg <br>
</td>
<td>
<br>7<br>
</td>
<td>
<br>3<br>
</td>
<td>
<br>1.2<br>
</td>
<td>
<br>27.4<br>
</td>
</tr>
<tr class="Last">
<td>
<br>Â Â Â 1,000 mg <br>
</td>
<td>
<br>13.6<br>
</td>
<td>
<br>2.5<br>
</td>
<td>
<br>1.3<br>
</td>
<td>
<br>50<br>
</td>
</tr>
</tbody>
</table>* Mean values of 12 healthy adult volunteers.<br><span class="Sup">â€  </span>Drug administered immediately after a meal.<br><br><span class="Bold"><br>Comparative Pharmacokinetic Properties: Cefuroxime axetil for oral 
suspension was not bioequivÂ­alent to cefuroxime axetil tablets when tested in 
healthy adults. The tablet and powder for oral suspension formulations are NOT 
substitutable on a milligram-per-milligram basis.Â  </span>The area under the 
curve for the suspension averaged 91%of that for the tablet, and the peak plasma 
concentration for the suspension averaged 71%of the peak plasma concentration of 
the tablets. Therefore, the safety and effectiveness of both the tablet and oral 
suspension formulations had to be established in separate clinical 
trials.<br><br><span class="Bold">Food Effect on Pharmacokinetics: 
</span>Absorption of the tablet is greater when taken after food (absolute 
bioavailability of cefuroxime axetil tablets increases from 37%to 52%). Despite 
this difference in absorption, the clinical and bacteriologic responses of 
patients were independent of food intake at the time of tablet administration in 
2 studies where this was assessed.<br>Â <br><span class="Bold">Renal Excretion: 
</span>Cefuroxime is excreted unchanged in the urine; in adults, approximately 
50%of the administered dose is recovered in the urine within 12 hours. The 
pharmacokinetics of cefuroxime in the urine of pediatric patients have not been 
studied at this time. Until further data are available, the renal 
pharmacokinetic properties of cefuroxime axetil established in adults should not 
be extrapolated to pediatric patients.<br>Â <br>Because cefuroxime is renally 
excreted, the serum half-life is prolonged in patients with reduced renal 
function. In a study of 20 elderly patients (mean age = 83.9 years) having a 
mean creatinine clearance of 34.9 mL/min, the mean serum elimination half-life 
was 3.5 hours. Despite the lower elimination of cefuroxime in geriatric 
patients, dosage adjustment based on age is not necessary (see <span class="Bold"><a href="#section-8.10">PRECAUTIONS: Geriatric 
Use</a></span>).<br>Â <br><span class="Bold">Microbiology: </span>The <span class="Italics">in vivo</span> bactericidal activity of cefuroxime axetil is due 
to cefuroximeâ€™s binding to essential target proteins and the resultant 
inhibition of cell-wall synthesis.<br>Â <br>Cefuroxime has bactericidal activity 
against a wide range of common pathogens, including many 
beta-lactamaseâ€“producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>. Cefuroxime is stable to many bacterial 
beta-lactamases, especially plasmid-mediated enzymes that are commonly found in 
enterobacteriaceae.<br>Â <br>Cefuroxime has been demonstrated to be active 
against most <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the following microorganisms both <span class="Italics">in 
vitro</span> and in clinical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> as described in the INDICATIONS AND 
USAGE section (see <span class="Bold"><a href="#section-5">INDICATIONS AND 
USAGE</a>Â </span>section).<br>Â <br><span class="Bold"><span class="Italics">Aerobic 
Gram-Positive Microorganisms:</span></span><br>Â <br><span class="Italics">Staphylococcus aureus </span>(including beta-lactamaseâ€“producing 
<span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>)<span class="Italics"><br>Streptococcus pneumoniae<br>Streptococcus 
pyogenes</span><br>Â <br><span class="Bold"><span class="Italics">Aerobic 
Gram-Negative Microorganisms:</span></span><br>Â <br><span class="Italics">Escherichia coli</span><br><span class="Italics">Haemophilus 
influenzae </span>(including beta-lactamaseâ€“producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>)<br><span class="Italics">Haemophilus parainfluenzae</span><br><span class="Italics">Klebsiella pneumoniae</span><br><span class="Italics">Moraxella 
catarrhalis </span>(including beta-lactamaseâ€“producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>)<br><span class="Italics">Neisseria gonorrhoeae </span>(including beta-lactamaseâ€“producing 
<span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>)<br>Â <br><span class="Bold"><span class="Italics">Spirochetes:</span></span><br>Â <br><span class="Italics">Borrelia burgdorferi</span><br>Â <br>Cefuroxime has 
been shown to be active <span class="Italics">in vitro</span> against most <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> 
of the following microorganisms; however, the clinical significance of these 
findings is unknown.<br>Â <br>Cefuroxime exhibits <span class="Italics">in 
vitro</span> <span class="product-label-link" type="condition" conceptid="4190299" conceptname="Broth microdilution susceptibility test">minimum inhibitory concentrations</span> (MICs) of 4 mcg/mL or less 
(systemic susceptible breakpoint) against most (â‰¥90%) <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the following 
microorganisms; however, the safety and effectiveness of cefuroxime in treating 
clinical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> due to these microorganisms have not been established in 
adequate and well-controlled trials.<br>Â <br><span class="Bold"><span class="Italics">Aerobic Gram-Positive Microorganisms:</span></span><br>Â <br><span class="Italics">Staphylococcus epidermidis</span><br><span class="Italics">Staphylococcus saprophyticus</span><br><span class="Italics">Streptococcus agalactiae </span><br>Â <br>NOTE: <span class="Italics">Listeria monocytogenes </span>and certain <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of enterococci, 
e.g., <span class="Italics">Enterococcus faecalis </span>(formerly <span class="Italics">Streptococcus faecalis</span>), are resistant to cefuroxime. 
Methicillin-resistant staphylococci are resistant to cefuroxime.<br>Â <br><span class="Bold"><span class="Italics">Aerobic Gram-Negative 
Microorganisms:</span></span><br>Â <br><span class="Italics">Morganella 
morganii</span><br><span class="Italics">Proteus inconstans</span><br><span class="Italics">Proteus mirabilis</span><br><span class="Italics">Providencia 
rettgeri</span><br>Â <br>NOTE: <span class="Italics">Pseudomonas </span>spp., 
<span class="Italics">Campylobacter </span>spp., <span class="Italics">Acinetobacter 
calcoaceticus</span>, <span class="Italics">Legionella </span>spp., and most 
<span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">Serratia </span>spp. and <span class="Italics">Proteus vulgaris </span>are resistant to most first- and 
second-generation cephalosporins. Some <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">Morganella 
morganii</span>, <span class="Italics">Enterobacter cloacae</span>, and <span class="Italics">Citrobacter </span>spp. have been shown by <span class="Italics">in 
vitro</span> tests to be resistant to cefuroxime and other 
cephalosporins.<br>Â <br><span class="Bold"><span class="Italics">Anaerobic 
Microorganisms:</span></span><br>Â <br><span class="Italics">Peptococcus 
niger</span><br>Â <br>NOTE: Most <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">Clostridium 
difficile </span>and <span class="Italics">Bacteroides fragilis </span>are 
resistant to cefuroxime.<br>Â <br><span class="Bold">Susceptibility Tests: <span class="Italics">Dilution Techniques: </span></span>Quantitative methods that are 
used to determine MICs provide reproducible estimates of the susceptibility of 
bacteria to antimicrobial compounds. One such standardized procedure uses a 
standardized dilution method<span class="Sup">1</span> (broth, agar, or 
microdilution) or equivalent with cefuroxime powder. The MIC values obtained 
should be interpreted according to the following criteria:<br><br><br><a name="i9d10aa50-b8d3-46cc-8898-33eb43fd5f80"></a><table border="0" cellpadding="0" cellspacing="0"><tbody class="Headless">
<tr class="First">
<td>
<br><span class="Underline">MIC 
(mcg/mL)</span><br>
</td>
<td>
<br><span class="Underline">Interpretation 
</span><br>
</td>
</tr>
<tr>
<td>
<br>â‰¤4<br>
</td>
<td>
<br>(S) Susceptible<br>
</td>
</tr>
<tr>
<td>
<br>8-16<br>
</td>
<td>
<br>(I) Intermediate<br>
</td>
</tr>
<tr class="Last">
<td>
<br>â‰¥32<br>
</td>
<td>
<br>(R) 
Resistant<br>
</td>
</tr>
</tbody></table>
<br>A report of â€œSusceptibleâ€? indicates 
that the pathogen, if in the blood, is likely to be inhibited by usually 
achievable concentrations of the antimicrobial compound in blood. A report of 
â€œIntermediateâ€? indicates that inhibitory concentrations of the antibiotic may be 
achieved if high dosage is used or if the <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> is confined to tissues or 
fluids in which high antibiotic concentrations are attained. This category also 
provides a buffer zone that prevents small, uncontrolled technical factors from 
causing major discrepancies in interpretation. A report of â€œResistantâ€? indicates 
that usually achievable concentrations of the antimicrobial compound in the 
blood are unlikely to be inhibitory and that other therapy should be 
selected.<br><br>Standardized susceptibility test procedures require the use of 
laboratory control microorganisms. Standard cefuroxime powder should give the 
following MIC values:Â <br><a name="iff1a8dea-a7bd-4a50-8130-0fadbc6024ef"></a><table border="0" cellpadding="0" cellspacing="0"><tbody class="Headless">
<tr class="First">
<td>
<br><span class="Underline">Microorganism</span><br>
</td>
<td>
<br><span class="Underline">MIC 
(mcg/mL)</span><br>
</td>
</tr>
<tr>
<td>
<br><span class="Italics">Escherichia coli </span>ATCC 25922<br>
</td>
<td>
<br>Â 2-8<br>
</td>
</tr>
<tr class="Last">
<td>
<br><span class="Italics">Staphylococcus aureus </span>ATCC 29213<br>
</td>
<td>
<br>Â 0.5-2<br>
</td>
</tr>
</tbody></table>
<span class="Bold"><span class="Italics"><br>Diffusion Techniques: </span></span>Quantitative methods that 
require measurement of zone diameters provide estimates of the susceptibility of 
bacteria to antimicrobial compounds. One such standardized procedure<span class="Sup">2</span> that has been recommended (for use with disks) to test the 
susceptibility of microorganisms to cefuroxime uses the 30 mcg cefuroxime disk. 
Interpretation involves correlation of the diameter obtained in the disk test 
with the MIC for cefuroxime.<br><br>Reports from the laboratory providing 
results of the standard single-disk susceptibility test with a 30 mcg cefuroxime 
disk should be interpreted according to the following criteria:Â <br><a name="id688533c-3c2a-44db-897a-e64d8e2c696e"></a><table border="0" cellpadding="0" cellspacing="0"><tbody class="Headless">
<tr class="First">
<td>
<br><span class="Underline">Zone 
Diameter (mm)</span><br>
</td>
<td>
<br><span class="Underline">Interpretation</span><br>
</td>
</tr>
<tr>
<td>
<br>â‰¥23<br>
</td>
<td>
<br>(S) Susceptible<br>
</td>
</tr>
<tr>
<td>
<br>15-22<br>
</td>
<td>
<br>(I) Intermediate<br>
</td>
</tr>
<tr class="Last">
<td>
<br>â‰¤14<br>
</td>
<td>
<br>(R) 
Resistant<br>
</td>
</tr>
</tbody></table>
<br>Interpretation should be as stated 
above for results using dilution techniques.<br><br>As with standard dilution 
techniques, diffusion methods require the use of laboratory control 
microorganisms. The 30 mcg cefuroxime disk provides the following zone diameters 
in these laboratory test quality control <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>:<br><a name="if306414e-f4df-4ac4-8bb6-e051c980fa9e"></a><table border="0" cellpadding="0" cellspacing="0"><tbody class="Headless">
<tr class="First">
<td>
<br><span class="Underline">Microorganism</span><br>
</td>
<td>
<br><span class="Underline">Zone Diameter 
(mm)</span><br>
</td>
</tr>
<tr>
<td>
<br><span class="Italics">Escherichia coli </span>ATCC 25922<br>
</td>
<td>
<br>20-26<br>
</td>
</tr>
<tr class="Last">
<td>
<br><span class="Italics">Staphylococcus aureus </span>ATCC 25923<br>
</td>
<td>
<br>27-35<br>
</td>
</tr>
</tbody></table>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">To reduce the development of drug-resistant bacteria and maintain the 
effectiveness of cefuroxime axetil and other antibacterial drugs, cefuroxime 
axetil should be used only to treat or prevent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or 
strongly suspected to be caused by susceptible bacteria. When culture and 
susceptibility information are available, they should be considered in selecting 
or modifying antibacterial therapy. In the absence of such data, local 
epidemiology and susceptibility patterns may contribute to the empiric selection 
of therapy.<br>Â <br><span class="Bold">NOTE: CEFUROXIME AXETIL TABLETS AND 
CEFUROXIME AXETIL FOR ORAL SUSPENSION ARE NOT BIOÂ­EQUIVALENT AND ARE NOT 
SUBSTITUTABLE ON A MILLIGRAM-PER-MILLIGRAM BASIS (SEE <a href="#section-4">CLINICAL PHARMACOLOGY</a>).</span><br>Â <br><span class="Bold">Cefuroxime Axetil Tablets: </span>Cefuroxime axetil tablets are 
indicated for the treatment of patients with mild to moderate <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> caused 
by susceptible <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the designated microorganisms in the conditions listed 
below:<br>Â <br><span class="Bold">1.Â Â Â  </span><span class="Bold"><span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">Pharyngitis</span>/<span class="product-label-link" type="condition" conceptid="4234533" conceptname="Tonsillitis">Tonsillitis</span> </span>caused by <span class="Italics">Streptococcus pyogenes.</span><br>Â <br><span class="Bold">NOTE: 
</span>The usual drug of choice in the treatment and prevention of streptococcal 
<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, including the prophylaxis of <span class="product-label-link" type="condition" conceptid="442313" conceptname="Rheumatic fever">rheumatic fever</span>, is penicillin given by 
the intramuscular route. Cefuroxime axetil tablets are generally effective in 
the eradication of streptococci from the nasopharynx; however, substantial data 
establishing the efficacy of cefuroxime in the subsequent prevention of 
<span class="product-label-link" type="condition" conceptid="442313" conceptname="Rheumatic fever">rheumatic fever</span> are not available. Please also note that in all clinical trials, 
all isolates had to be sensitive to both penicillin and cefuroxime. There are no 
data from adequate and well-controlled trials to demonstrate the effectiveness 
of cefuroxime in the treatment of penicillin-resistant <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">Streptococcus pyogenes.</span><br>Â <br><span class="Bold">2.Â Â Â Â </span><span class="Bold">Acute Bacterial <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">Otitis Media</span> 
</span>caused by <span class="Italics">Streptococcus pneumoniae</span>, <span class="Italics">Haemophilus influenzae </span>(including beta-lactamaseâ€“producing 
<span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>), <span class="Italics">Moraxella catarrhalis </span>(including 
beta-lactamaseâ€“producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>), or <span class="Italics">Streptococcus 
pyogenes.</span><br>Â <br><span class="Bold">3.Â Â Â  </span><span class="Bold">Acute 
Bacterial <span class="product-label-link" type="condition" conceptid="4228816" conceptname="Maxillary sinusitis">Maxillary Sinusitis</span> </span>caused by <span class="Italics">Streptococcus 
pneumoniae </span>or <span class="Italics">Haemophilus influenzae 
</span>(non-beta-lactamaseâ€“producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> only). (See <span class="Bold"><a href="#section-13">CLINICAL STUDIES</a></span> section.)<br>Â <br><span class="Bold">NOTE: </span>In view of the insufficient numbers of isolates of 
beta-lactamaseâ€“producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">Haemophilus influenzae 
</span>and <span class="Italics">Moraxella catarrhalis </span>that were obtained 
from clinical trials with cefuroxime axetil tablets for patients with acute 
bacterial <span class="product-label-link" type="condition" conceptid="4228816" conceptname="Maxillary sinusitis">maxillary sinusitis</span>, it was not possible to adequately evaluate the 
effectiveness of cefuroxime axetil tablets for <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinus infections</span> known, 
suspected, or considered potentially to be caused by beta-lactamaseâ€“producing 
<span class="Italics">Haemophilus influenzae </span>or <span class="Italics">Moraxella catarrhalis</span>.<br>Â <br><span class="Bold">4.Â Â Â Â </span><span class="Bold">Acute Bacterial Exacerbations of 
<span class="product-label-link" type="condition" conceptid="255841" conceptname="Chronic bronchitis">Chronic Bronchitis</span> and Secondary <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">Bacterial Infections</span> of <span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">Acute Bronchitis</span> 
</span>caused by <span class="Italics">Streptococcus pneumoniae</span>, <span class="Italics">Haemophilus influenzae </span>(beta-lactamase negative <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>), 
or <span class="Italics">Haemophilus parainfluenzae </span>(beta-lactamase 
negative <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>). (See <span class="Bold"><a href="#section-11">DOSAGE AND 
ADMINISTRATION</a></span> section and <span class="Bold"><a href="#section-13">CLINICAL STUDIES</a></span> section.)<br>Â <br><span class="Bold">5.Â Â Â  </span><span class="Bold">Uncomplicated Skin and Skin-Structure 
<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> </span>caused by <span class="Italics">Staphylococcus aureus 
</span>(including beta-lactamaseâ€“producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>) or <span class="Italics">Streptococcus pyogenes.</span><br>Â <br><span class="Bold">6.Â Â Â Â </span><span class="Bold">Uncomplicated <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary Tract Infections</span> 
</span>caused by <span class="Italics">Escherichia coli </span>or <span class="Italics">Klebsiella pneumoniae</span>.<br>Â <br><span class="Bold">7.Â Â Â Â </span><span class="Bold">Uncomplicated <span class="product-label-link" type="condition" conceptid="433417" conceptname="Gonorrhea">Gonorrhea</span>, 
</span>urethral and endocervical, caused by penicillinase-producing and 
non-penicillinaseâ€“producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">Neisseria gonorrhoeae 
</span>and uncomplicated <span class="product-label-link" type="condition" conceptid="433417" conceptname="Gonorrhea">gonorrhea</span>, rectal, in females, caused by 
non-penicillinaseâ€“producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">Neisseria 
gonorrhoeae</span>.<br>Â <br><span class="Bold">8.Â Â Â Early <span class="product-label-link" type="condition" conceptid="440638" conceptname="Lyme disease">Lyme Disease</span> (<span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span> 
migrans) </span>caused by <span class="Italics">Borrelia burgdorferi.</span><a href="http://"></a></p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Cefuroxime axetil products are contraindicated in patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span> to 
the cephalosporin group of antibiotics.<a href="http://"></a></p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<p class="First"><span class="Bold">CEFUROXIME AXETIL TABLETS AND CEFUROXIME AXETIL FOR ORAL 
SUSPENSION ARE NOT BIOEQUIVALENT AND ARE THEREFORE NOT SUBSTITUTABLE ON A 
MILLIGRAM-PER-MILLIGRAM BASIS (SEE <a href="#section-4">CLINICAL 
PHARMACOLOGY</a>).</span><br>Â <br><span class="Bold">BEFORE THERAPY WITH 
CEFUROXIME AXETIL PRODUCTS IS INSTITUTED, CAREFUL INQUIRY SHOULD BE MADE TO 
DETERMINE WHETHER THE PATIENT HAS HAD PREVIOUS <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">HYPERSENSITIVITY REACTIONS</span> TO 
CEFUROXIME AXETIL PRODUCTS, OTHER CEPHALOSPORINS, PENICILLINS, OR OTHER DRUGS. 
IF THIS PRODUCT IS TO BE GIVEN TO PENICILLIN-SENSITIVE PATIENTS, CAUTION SHOULD 
BE EXERCISED BECAUSE CROSS-<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">HYPERSENSITIVITY</span> AMONG BETA-LACTAM ANTIBIOTICS HAS 
BEEN CLEARLY DOCUMENTED AND MAY OCCUR IN UP TO 10%OF PATIENTS WITH A HISTORY OF 
<span class="product-label-link" type="condition" conceptid="439224" conceptname="Drug allergy">PENICILLIN ALLERGY</span>. IF A CLINICALLY SIGNIFICANT <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">ALLERGIC REACTION</span> TO CEFUROXIME 
AXETIL PRODUCTS OCCURS, DISCONTINUE THE DRUG AND INSTITUTE APPROPRIATE THERAPY. 
SERIOUS ACUTE <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">HYPERSENSITIVITY REACTIONS</span> MAY REQUIRE TREATMENT WITH EPINEPHRINE 
AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS 
ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS 
CLINICALLY INDICATED.</span><br>Â <br><span class="Italics">Clostridium 
difficile</span>Â  associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (CDAD) has been reported with use of 
nearly all antibacterial agents, including cefuroxime, and may range in severity 
from mild <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> to fatal <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>. Treatment with antibacterial agents alters 
the normal flora of the colon leading to overgrowth of <span class="Italics">C. 
difficile</span>.<br>Â <br><span class="Italics">C. difficile</span>Â  produces 
toxins A and B which contribute to the development of CDAD. Hypertoxin producing 
<span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">C. difficile</span> cause increased morbidity and 
mortality, as these <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> can be refractory to antimicrobial therapy and 
may require colectomy. CDAD must be considered in all patients who present with 
<span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> following antibiotic use. Careful medical history is necessary since 
CDAD has been reported to occur over two months after the administration of 
antibacterial agents.<br><br>If CDAD is suspected or confirmed, ongoing 
antibiotic use not directed against <span class="Italics">C. difficile</span> may 
need to be discontinued. Appropriate fluid and electrolyte management, protein 
supplementation, antibiotic treatment of <span class="Italics">C. 
difficile</span>, and surgical evaluation should be instituted as clinically 
indicated.<a href="http://"></a></p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<a href="http://"></a>General<br>As with other broad-spectrum 
antibiotics, prolonged administration of cefuroxime axetil may result in 
overgrowth of nonsusceptible microorganisms. If <span class="product-label-link" type="condition" conceptid="4105019" conceptname="Superimposed infection">superinfection</span> occurs during 
therapy, appropriate measures should be taken.<br>Â <br>Cephalosporins, including 
cefuroxime axetil, should be given with caution to patients receiving concurrent 
treatment with potent diuretics because these diuretics are suspected of 
adversely affecting renal function.<br>Â <br>Cefuroxime axetil, as with other 
broad-spectrum antibiotics, should be prescribed with caution in individuals 
with a history of <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>. The safety and effectiveness of cefuroxime axetil 
have not been established in patients with gastrointestinal <span class="product-label-link" type="condition" conceptid="194993" conceptname="Intestinal malabsorption">malabsorption</span>. 
Patients with gastrointestinal <span class="product-label-link" type="condition" conceptid="194993" conceptname="Intestinal malabsorption">malabsorption</span> were excluded from participating in 
clinical trials of cefuroxime axetil.<br>Â <br>Cephalosporins may be associated 
with a <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span> in <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> activity. Those at risk include patients with renal 
or <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> or poor nutritional state, as well as patients receiving a 
protracted course of antimicrobial therapy, and patients previously stabilized 
on anticoagulant therapy. <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">Prothrombin</span> time should be monitored in patients at 
risk and exogenous Vitamin K administered as indicated.<br>Â <br>Prescribing 
cefuroxime axetil in the absence of a proven or strongly suspected bacterial 
<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> or a <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> indication is unlikely to provide benefit to the 
patient and increases the risk of the development of drug-resistant 
bacteria.<br>Â <br><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> is a common problem caused by antibiotics which 
usually ends when the antibiotic is discontinued. Sometimes after starting 
treatment with antibiotics, patients can develop watery and <span class="product-label-link" type="condition" conceptid="443530" conceptname="Hematochezia">bloody stools</span> (with 
or without <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach cramps</span> and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>) even as late as two or more months after 
having taken the last dose of the antibiotic. If this occurs, patients should 
contact their physician as soon as possible.<a href="http://"></a><a href="http://"></a>Information for Patients/Caregivers 
(Pediatric)<br>1.Â  During clinical trials, the tablet was tolerated by 
pediatric patients old enough to swallow the cefuroxime axetil tablet whole. The 
crushed tablet has a strong, persistent, bitter taste and should not be 
administered to pediatric patients in this manner. Pediatric patients who cannot 
swallow the tablet whole should receive the oral suspension.<br><br>2.Â  Patients 
should be counseled that antibacterial drugs, including cefuroxime axetil, 
should only be used to treat <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infections</span>. They do not treat viral 
<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> (e.g., the <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">common cold</span>). When cefuroxime axetil is prescribed to 
treat a <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span>, patients should be told that although it is common 
to feel better early in the course of therapy, the medication should be taken 
exactly as directed. Skipping doses or not completing the full course of therapy 
may: (1) decrease the effectiveness of the immediate treatment, and (2) increase 
the likelihood that bacteria will develop resistance and will not be treatable 
by cefuroxime axetil or other antibacterial drugs in the future.<a href="http://"></a><a href="http://"></a>Drug/Laboratory Test Interactions<br>A 
false-positive reaction for glucose in the urine may occur with copper reduction 
tests (Benedictâ€™s or Fehlingâ€™s solution or with CLINITEST<span class="Sup">Â®</span> tablets), but not with enzyme-based tests for <span class="product-label-link" type="condition" conceptid="434164" conceptname="Glycosuria">glycosuria</span> 
(e.g., CLINISTIX<span class="Sup">Â®</span>). As a false-negative result may occur 
in the ferricyanide test, it is recommended that either the glucose oxidase or 
hexokinase method be used to determine blood/plasma glucose levels in patients 
receiving cefuroxime axetil. The presence of cefuroxime does not interfere with 
the assay of serum and urine creatinine by the alkaline picrate method.<a href="http://"></a><a href="http://"></a>Drug/Drug Interactions<br>Concomitant 
administration of probenecid with cefuroxime axetil tablets increases the area 
under the serum concentration versus time curve by 50%. The peak serum 
cefuroxime concentration after a 1.5 g single dose is greater when taken with 1 
g of probenecid (mean = 14.8 mcg/mL) than without probenecid (mean = 12.2 
mcg/mL).<br>Â <br>Drugs that reduce gastric acidity may result in a lower 
bioavailability of cefuroxime axetil compared with that of fasting state and 
tend to cancel the effect of postprandial absorption.<br>Â <br>In common with 
other antibiotics, cefuroxime axetil may affect the gut flora, leading to lower 
estrogen reabsorption and reduced efficacy of combined oral 
estrogen/progesterone contraceptives.<a href="http://"></a><a href="http://"></a>Carcinogenesis,Mutagenesis,Impairment Of 
Fertility<br>Although lifetime studies in animals have not been performed 
to evaluate carcinogenic potential, no mutagenic activity was found for 
cefuroxime axetil in a battery of bacterial mutation tests. Positive results 
were obtained in an <span class="Italics">in vitro</span> chromosome aberration 
assay; however, negative results were found in an <span class="Italics">in 
vivo</span> micronucleus test at doses up to 1.5 g/kg. Reproduction studies in 
rats at doses up to 1,000 mg/kg/day (9 times the recommended maximum human dose 
based on mg/m<span class="Sup">2</span>) have revealed no impairment of 
fertility.<a href="http://"></a><a href="http://"></a>Pregnancy<a href="http://"></a><a href="http://"></a>Teratogenic Effects<br>Pregnancy Category B. 
Reproduction studies have been performed in mice at doses up to 3,200 mg/kg/day 
(14 times the recommended maximum human dose based on mg/m<span class="Sup">2</span>) and in rats at doses up to 1,000 mg/kg/day (9 times the 
recommended maximum human dose based on mg/m<span class="Sup">2</span>) and have 
revealed no evidence of impaired fertility or harm to the fetus due to 
cefuroxime axetil. There are, however, no adequate and well-controlled studies 
in pregnant women. Because animal reproduction studies are not always predictive 
of human response, this drug should be used during pregnancy only if clearly 
needed.<a href="http://"></a><a href="http://"></a>Labor And Delivery<br>Cefuroxime axetil has not 
been studied for use during labor and delivery.<a href="http://"></a><a href="http://"></a>Nursing Mothers<br>Because cefuroxime is 
excreted in human milk, consideration should be given to discontinuing nursing 
temporarily during treatment with cefuroxime axetil.<a href="http://"></a><a href="http://"></a>Pediatric Use<br>The safety and effectiveness of 
cefuroxime axetil have been established for pediatric patients aged 3 months to 
12 years for acute bacterial <span class="product-label-link" type="condition" conceptid="4228816" conceptname="Maxillary sinusitis">maxillary sinusitis</span> based upon its approval in 
adults. Use of cefuroxime axetil in pediatric patients is supported by 
pharmacokinetic and safety data in adults and pediatric patients, and by 
clinical and microbiological data from adequate and well-controlled studies of 
the treatment of acute bacterial <span class="product-label-link" type="condition" conceptid="4228816" conceptname="Maxillary sinusitis">maxillary sinusitis</span> in adults and of acute 
<span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">otitis media</span> with <span class="product-label-link" type="condition" conceptid="4215818" conceptname="Effusion">effusion</span> in pediatric patients. It is also supported by 
postmarketing adverse events surveillance (see <span class="Bold"><a href="#section-4">CLINICAL PHARMACOLOGY</a></span>, <span class="Bold"><a href="#section-5">INDICATIONS AND USAGE</a></span>, <span class="Bold"><a href="#section-9">ADVERSE REACTIONS</a></span>, <span class="Bold"><a href="#section-11">DOSAGE AND ADMINISTRATION</a></span>, and <span class="Bold"><a href="#section-13">CLINICAL STUDIES</a></span>).<a href="http://"></a><a href="http://"></a>Geriatric Use<br>Of the total number of subjects 
who received cefuroxime axetil in 20 clinical studies of cefuroxime axetil, 375 
were 65 and over while 151 were 75 and over. No overall differences in safety or 
effectiveness were observed between these subjects and younger adult subjects. 
The geriatric patients reported somewhat fewer gastrointestinal events and less 
frequent <span class="product-label-link" type="condition" conceptid="198363" conceptname="Candidiasis of vagina">vaginal candidiasis</span> compared with patients aged 12 to 64 years old; 
however, no clinically significant differences were reported between the elderly 
and younger adult patients. Other reported clinical experience has not 
identified differences in responses between the elderly and younger adult 
patients.<a href="http://"></a>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First"><span class="Bold">CEFUROXIME AXETIL TABLETS IN CLINICAL TRIALS: Multiple-Dose 
Dosing Regimens: <span class="Italics">7 to 10 Days Dosing: </span></span>Using 
multiple doses of cefuroxime axetil tablets, 912 patients were treated with 
cefuroxime axetil (125 to 500 mg twice daily). There were no <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> or permanent 
disabilities thought related to <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">drug toxicity</span>. Twenty (2.2%) patients 
discontinued medication due to adverse events thought by the investigators to be 
possibly, probably, or almost certainly related to <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">drug toxicity</span>. Seventeen 
(85%) of the 20 patients who discontinued therapy did so because of 
<span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal disturbances</span>, including <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and 
<span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>. The percentage of cefuroxime axetil tablet-treated patients who 
discontinued study drug because of adverse events was very similar at daily 
doses of 1,000, 500, and 250 mg (2.3%, 2.1%, and 2.2%, respectively). However, 
the incidence of gastrointestinal adverse events increased with the higher 
recommended doses.<br>Â <br>The following adverse events were thought by the 
investigators to be possibly, probably, or almost certainly related to 
cefuroxime axetil tablets in multiple-dose clinical trials (n = 912 cefuroxime 
axetil-treated patients).<br></p>
<a name="id71499a0-909a-453b-86a6-4bab5a0e501d"></a><table border="0" cellpadding="0" cellspacing="0">
<caption><span>Table 2. Adverse Reactionsâ€” Cefuroxime Axetil Tablets Multiple-Dose 
Dosing Regimensâ€”Clinical Trials </span></caption>
<tbody class="Headless">
<tr class="First">
<td>
<br>Â  Incidence â‰¥1%Â Â Â <br>
</td>
<td>
<br>Â  <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span>/loose stoolsÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â 3.7%Â Â Â Â Â Â  
<br>Â  <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>/vomitingÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â  3%Â Â Â Â Â Â <br>Â  Transient elevation in 
ASTÂ Â Â Â Â Â  Â 2%Â Â Â Â Â Â  <br>Â  Transient elevation in ALTÂ Â Â Â Â Â  1.6%Â Â Â Â Â Â <br>Â  
EosinophiliaÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 1.1%Â Â Â Â Â Â <br>Â  Transient elevation in 
LDHÂ Â Â Â Â Â Â  1%Â Â Â Â Â Â </td>
</tr>
<tr class="Last">
<td>
<br>Â  Incidence<br>Â  &lt;1%but 
&gt;0.1%Â Â Â </td>
<td>
<br>Â  <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span> <br>Â  <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal cramps</span> <br>Â  
<span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">Flatulence</span> <br>Â  <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Indigestion</span> <br>Â  <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span> <br>Â  <span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">Vaginitis</span> <br>Â  Vulvar <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itch</span> 
<br>Â  <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span> <br>Â  <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">Hives</span> <br>Â  <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">Itch</span> <br>Â  <span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">Dysuria</span> <br>Â  <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">Chills</span> <br>Â  <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">Chest pain</span> 
<br>Â  <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Shortness of breath</span> <br>Â  <span class="product-label-link" type="condition" conceptid="4094986" conceptname="Ulcer of mouth">Mouth ulcers</span> <br>Â  <span class="product-label-link" type="condition" conceptid="4222234" conceptname="Tongue swelling">Swollen tongue</span> <br>Â  
<span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Sleepiness</span> <br>Â  <span class="product-label-link" type="condition" conceptid="4241197" conceptname="Thirst">Thirst</span> <br>Â  <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span> <br>Â  Positive Coombs 
test</td>
</tr>
</tbody>
</table>
<br><span class="Bold"><span class="Italics">5-Day 
Experience (see <a href="#section-13">CLINICAL STUDIES</a>Â section): 
</span></span>In clinical trials using cefuroxime axetil in a dose of 250 mg 
twice daily in the treatment of secondary <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infections</span> of acute 
<span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">bronchitis</span>, 399 patients were treated for 5 days and 402 patients were treated 
for 10 days. No difference in the occurrence of adverse events was found between 
the 2 regimens.<br><span class="Bold"><span class="Italics"><br>In Clinical Trials 
for Early <span class="product-label-link" type="condition" conceptid="440638" conceptname="Lyme disease">Lyme Disease</span> With 20 Days Dosing: </span></span>Two multicenter trials 
assessed cefuroxime axetil tablets 500 mg twice a day for 20 days. The most 
common drug-related adverse experiences were <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (10.6%of patients), 
Jarisch-Herxheimer reaction (5.6%), and <span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">vaginitis</span> (5.4%). Other adverse 
experiences occurred with frequencies comparable to those reported with 7 to 10 
days dosing.<br>Â <br><span class="Bold">Single-Dose Regimen for Uncomplicated 
<span class="product-label-link" type="condition" conceptid="433417" conceptname="Gonorrhea">Gonorrhea</span>: </span>In clinical trials using a single dose of cefuroxime axetil 
tablets, 1,061 patients were treated with the recommended dosage of cefuroxime 
axetil (1,000 mg) for the treatment of uncomplicated <span class="product-label-link" type="condition" conceptid="433417" conceptname="Gonorrhea">gonorrhea</span>. There were no 
<span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> or permanent disabilities thought related to <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">drug toxicity</span> in these 
studies.<br>Â <br>The following adverse events were thought by the investigators 
to be possibly, probably, or almost certainly related to cefuroxime axetil in 
1,000 mg single-dose clinical trials of cefuroxime axetil tablets in the 
treatment of uncomplicated <span class="product-label-link" type="condition" conceptid="433417" conceptname="Gonorrhea">gonorrhea</span> conducted in the United States.Â Â <br><a name="if83f1682-97c2-48f3-84b8-8d98b0ec2e1a"></a><table border="0" cellpadding="0" cellspacing="0">
<caption><span>Table 3. Adverse Reactionsâ€” Cefuroxime Axetil Tablets 1-g Single-Dose 
Regimen for Uncomplicated Gonorrheaâ€”Clinical Trials </span></caption>
<tbody class="Headless">
<tr class="First">
<td>
<br>Â  Incidence â‰¥1%Â Â Â <br>
</td>
<td>
<br>Â  
<span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>/vomitingÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 6.8%Â Â Â Â Â Â <br>Â  
DiarrheaÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 4.2%Â Â Â Â Â Â </td>
</tr>
<tr class="Last">
<td>
<br>Â  Incidence<br>Â  &lt;1%but 
&gt;0.1%Â Â Â </td>
<td>
<br>Â  <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span><br>Â  <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span><br>Â  
<span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">Erythema</span><br>Â  <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span><br>Â  <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span><br>Â  <span class="product-label-link" type="condition" conceptid="198363" conceptname="Candidiasis of vagina">Vaginal candidiasis</span><br>Â  Vaginal <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itch</span><br>Â  
<span class="product-label-link" type="condition" conceptid="4155070" conceptname="Vaginal discharge">Vaginal discharge</span><br>Â  <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span><br>Â  <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span><br>Â  <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span><br>Â  Muscle 
<span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">cramps</span><br>Â  <span class="product-label-link" type="condition" conceptid="4050941" conceptname="Muscle rigidity">Muscle stiffness</span><br>Â  <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">Muscle spasm</span> of neck<br>Â  Tightness/<span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in 
chest<br>Â  <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span>/<span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in urethra <br>Â  <span class="product-label-link" type="condition" conceptid="4167250" conceptname="Renal pain">Kidney pain</span> <br>Â  <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">Tachycardia</span><br>Â  
<span class="product-label-link" type="condition" conceptid="4339090" conceptname="Trismus">Lockjaw</span>-type reaction</td>
</tr>
</tbody>
</table>
<br><span class="Bold">POSTMARKETING EXPERIENCE WITH CEFUROXIME AXETIL PRODUCTS<br>Â <br></span>In 
addition to adverse events reported during clinical trials, the following events 
have been identified during clinical practice in patients treated with 
cefuroxime axetil tablets or with cefuroxime axetil for oral suspension and were 
reported spontaneously. Data are generally insufficient to allow an estimate of 
incidence or to establish causation.<span class="Bold"><span class="Italics"><br><br>General: </span></span>The following <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> have 
been reported: <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="432522" conceptname="Transfusion reaction due to serum protein reaction">serum sickness</span>-like 
reaction, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>.<span class="Bold"><span class="Italics"><br><br>Gastrointestinal: </span></span><span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">Pseudomembranous colitis</span> (see <span class="Bold"><a href="#section-7">WARNINGS</a></span>).<br>Â <br><span class="Bold"><span class="Italics">Hematologic: </span></span><span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">Hemolytic anemia</span>, 
<span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, and increased <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> 
time.<br>Â <br><span class="Bold"><span class="Italics">Hepatic: 
</span></span><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic impairment</span> including <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> and <span class="product-label-link" type="condition" conceptid="4143915" conceptname="Cholestasis">cholestasis</span>, 
<span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>.<br>Â <br><span class="Bold"><span class="Italics">Neurologic: 
</span></span><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizure</span>.<br>Â <br><span class="Bold"><span class="Italics">Skin: 
</span></span><span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">Erythema multiforme</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, toxic epidermal 
necrolysis.<br>Â <br><span class="Bold"><span class="Italics">Urologic: 
</span></span>Renal dysfunction.<br>Â <br><span class="Bold">CEPHALOSPORIN-CLASS 
ADVERSE REACTIONS</span><br>Â <br>In addition to the adverse reactions listed 
above that have been observed in patients treated with cefuroxime axetil, the 
following adverse reactions and altered laboratory tests have been reported for 
cephalosporin-class antibiotics: <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">toxic nephropathy</span>, <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span>, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>, 
increased BUN, increased creatinine, false-positive test for urinary glucose, 
increased alkaline phosphatase, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, elevated bilirubin, and 
<span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>.<br>Â <br>Several cephalosporins have been implicated in 
triggering <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, particularly in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> when the 
dosage was not reduced (see <span class="Bold"><a href="#section-11">DOSAGE AND 
ADMINISTRATION</a>Â </span>and <span class="Bold"><a href="#section-10">OVERDOSAGE</a></span>). If <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> associated with drug 
therapy occur, the drug should be discontinued. Anticonvulsant therapy can be 
given if clinically indicated.<a href="http://"></a><br>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">Overdosage of cephalosporins can cause cerebral irritation leading to 
<span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>. Serum levels of cefuroxime can be reduced by hemodialysis and 
peritoneal dialysis.<a href="http://"></a></p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First"><span class="Bold">NOTE: CEFUROXIME AXETIL TABLETS AND CEFUROXIME AXETIL FOR ORAL 
SUSPENSION ARE NOT BIOEQUIVALENT AND ARE NOT SUBSTITUTABLE ON A 
MILLIGRAM-PER-MILLIGRAM BASIS (SEE <a href="#section-4">CLINICAL 
PHARMACOLOGY</a>).</span><br>Â  <br></p>
<a name="ib61a68cb-e5d8-457c-88d9-4d3d126c8720"></a><table border="0" cellpadding="0" cellspacing="0">
<caption><span>Table 4. Cefuroxime Axetil Tablets (May be administered without regard 
to meals.) </span></caption>
<tbody class="Headless">
<tr class="First">
<td>
<br>Population/<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span><br>
</td>
<td>
<br>Dosage<br>
</td>
<td>
<br>Â Â  Duration<br>Â Â  (days)</td>
</tr>
<tr><td>
<br><span class="Bold">Adolescents 
and Adults (13 years and older)</span><br>
</td></tr>
<tr>
<td>
<br><span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">Pharyngitis</span>/<span class="product-label-link" type="condition" conceptid="4234533" conceptname="Tonsillitis">tonsillitis</span> <br>
</td>
<td>
<br>250 mg b.i.d.<br>
</td>
<td>
<br>10<br>
</td>
</tr>
<tr>
<td>
<br>Acute bacterial <span class="product-label-link" type="condition" conceptid="4228816" conceptname="Maxillary sinusitis">maxillary sinusitis</span> 
<br>
</td>
<td>
<br>250 mg b.i.d.<br>
</td>
<td>
<br>10<br>
</td>
</tr>
<tr>
<td>
<br>Acute bacterial exacerbations 
of<br><span class="product-label-link" type="condition" conceptid="255841" conceptname="Chronic bronchitis">chronic bronchitis</span> </td>
<td>
<br>250 or 500 mg b.i.d.<br>
</td>
<td>
<br>10*<br>
</td>
</tr>
<tr>
<td>
<br>Secondary <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infections</span><br>of 
<span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">acute bronchitis</span> </td>
<td>
<br>250 or 500 mg b.i.d.<br>
</td>
<td>
<br>5-10<br>
</td>
</tr>
<tr>
<td>
<br>Uncomplicated skin and<br>skinÂ­-structure 
<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> </td>
<td>
<br>250 or 500 mg b.i.d.<br>
</td>
<td>
<br>10<br>
</td>
</tr>
<tr>
<td>
<br>Uncomplicated urinary<br>tract <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> 
</td>
<td>
<br>250 mg b.i.d.<br>
</td>
<td>
<br>7-10<br>
</td>
</tr>
<tr>
<td>
<br>Uncomplicated <span class="product-label-link" type="condition" conceptid="433417" conceptname="Gonorrhea">gonorrhea</span> <br>
</td>
<td>
<br>1,000 mg once<br>
</td>
<td>
<br>single dose<br>
</td>
</tr>
<tr>
<td>
<br>Early <span class="product-label-link" type="condition" conceptid="440638" conceptname="Lyme disease">Lyme disease</span> <br>
</td>
<td>
<br>500 mg b.i.d.<br>
</td>
<td>
<br>20<br>
</td>
</tr>
<tr><td>
<br><span class="Bold">Pediatric 
Patients (who can swallow tablets whole)</span><br>
</td></tr>
<tr>
<td>
<br>Acute <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">otitis media</span> <br>
</td>
<td>
<br>250 mg b.i.d.<br>
</td>
<td>
<br>10<br>
</td>
</tr>
<tr class="Last">
<td>
<br>Acute bacterial <span class="product-label-link" type="condition" conceptid="4228816" conceptname="Maxillary sinusitis">maxillary sinusitis</span> 
<br>
</td>
<td>
<br>250 mg b.i.d.<br>
</td>
<td>
<br>10<br>
</td>
</tr>
</tbody>
</table>* The safety and effectiveness of cefuroxime axetil administered<br>Â  for less 
than 10 days in patients with acute exacerbations of<br>Â  <span class="product-label-link" type="condition" conceptid="255841" conceptname="Chronic bronchitis">chronic bronchitis</span> 
have not been established.<br><br><span class="Bold">Patients With <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal Failure</span>: </span>The safety and efficacy 
of cefuroxime axetil in patients with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span> have not been established. 
Since cefuroxime is renally eliminated, its half-life will be prolonged in 
patients with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>.<a href="http://"></a>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First"><span class="Bold"></span><span class="Bold">Cefuroxime Axetil Tablets, USP 250 mg 
</span>of cefuroxime (as cefuroxime axetil), areÂ  white to off-white, uncoated, 
capsule-shaped tablets with â€œA33â€? debossed on one side and plain on the other 
side.<br>Â <br></p>
<a name="i8aeca7dd-11a6-458b-8627-5b4cfe3b89f4"></a><table width="30%"><tbody class="Headless">
<tr class="First">
<td>Bottles of 20<br>
</td>
<td>NDC 54868-4987-0<br>
</td>
</tr>
<tr class="Last">
<td>Bottles of 30<br>
</td>
<td>NDC 54868-4987-1<br>
</td>
</tr>
</tbody></table>
<p><br>Â <span class="Bold">Cefuroxime Axetil Tablets, USP 500 mg 
</span>of cefuroxime (as cefuroxime axetil), areÂ  white to off-white, uncoated, 
capsule-shaped tablets with â€œA34â€? debossed on one side and plain on the other 
side.<br>Â <br></p>
<a name="i20746c9e-a294-4ee2-8881-c96f28830ff7"></a><table width="30%"><tbody class="Headless">
<tr class="First">
<td>Bottles of 15<br>
</td>
<td>NDC 54868-5022-2<br>
</td>
</tr>
<tr>
<td>Bottles of 20<br>
</td>
<td>NDC 54868-5022-1<br>
</td>
</tr>
<tr>
<td>Bottles of 30<br>
</td>
<td>NDC 54868-5022-0<br>
</td>
</tr>
<tr class="Last">
<td>Bottles of 60<br>
</td>
<td>NDC 54868-5022-3<br>
</td>
</tr>
</tbody></table>
<p><span class="Bold"><br>Store at 20Â° to 25Â°C (68Â° to 77Â°F); 
excursions permitted to 15Â° to 30Â°C (59Â° to 86Â°F) [see USP Controlled Room 
Temperature]. Replace cap securely after each opening.</span><a href="http://"></a></p>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="section-12"></a><p></p>
<h1>CLINICAL STUDIES</h1>
<p class="First"><span class="Bold">Cefuroxime Axetil Tablets: <span class="Italics">Acute Bacterial 
<span class="product-label-link" type="condition" conceptid="4228816" conceptname="Maxillary sinusitis">Maxillary Sinusitis</span>: </span></span>One adequate and well-controlled study was 
performed in patients with acute bacterial <span class="product-label-link" type="condition" conceptid="4228816" conceptname="Maxillary sinusitis">maxillary sinusitis</span>. In this study 
each patient had a maxillary sinus aspirate collected by sinus puncture before 
treatment was initiated for presumptive acute bacterial <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinusitis</span>. All patients 
had to have radiographic and clinical evidence of <span class="product-label-link" type="condition" conceptid="141323" conceptname="Acute maxillary sinusitis">acute maxillary sinusitis</span>. As 
shown in the following summary of the study, the general clinical effectiveness 
of cefuroxime axetil tablets was comparable to an oral antimicrobial agent that 
contained a specific betalactamase inhibitor in treating acute maxillary 
<span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinusitis</span>. However, sufficient microbiology data were obtained to demonstrate 
the effectiveness of cefuroxime axetil tablets in treating acute bacterial 
<span class="product-label-link" type="condition" conceptid="4228816" conceptname="Maxillary sinusitis">maxillary sinusitis</span> due only to <span class="Italics">Streptococcus pneumoniae 
</span>or non-beta-lactamaseâ€“producing <span class="Italics">Haemophilus 
influenzae. </span>An insufficient number of beta-lactamaseâ€“producing <span class="Italics">Haemophilus influenzae </span>and <span class="Italics">Moraxella 
catarrhalis </span>isolates were obtained in this trial to adequately evaluate 
the effectiveness of cefuroxime axetil tablets in the treatment of acute 
bacterial <span class="product-label-link" type="condition" conceptid="4228816" conceptname="Maxillary sinusitis">maxillary sinusitis</span> due to these 2 organisms.<br>Â <br>This study 
enrolled 317 adult patients, 132 patients in the United States and 185 patients 
in South America. Patients were randomized in a 1:1 ratio to cefuroxime axetil 
250 mg twice daily or an oral antimicrobial agent that contained a specific 
beta-lactamase inhibitor. An intent-to-treat analysis of the submitted clinical 
data yielded the following results:<br>Â 
</p>
<a name="i87913924-51f5-4d7c-8e00-e2e771e4db8e"></a><table border="0" cellpadding="0" cellspacing="0">
<caption><span>Table 5. Clinical Effectiveness of Cefuroxime Axetil Tablets Compared 
to Beta-Lactamase Inhibitor-Containing Control Drug in the Treatment of Acute 
Bacterial <span class="product-label-link" type="condition" conceptid="4228816" conceptname="Maxillary sinusitis">Maxillary Sinusitis</span> </span></caption>
<tbody class="Headless">
<tr class="First">
<td>
<br>Â <br>
</td>
<td>
<br>Â Â Â Â Â Â U.S. Patients*<br>
</td>
<td>
<br>South American Patients<span class="Sup">â€ </span><br>
</td>
</tr>
<tr>
<td>
<br>Cefuroxime Axetil<br>(n = 
49)</td>
<td>
<br>Control<br>(n = 43)</td>
<td>
<br>Cefuroxime Axetil<br>Â Â Â Â  (n = 87)</td>
<td>
<br>Control<br>(n = 89)</td>
</tr>
<tr>
<td>
<br>Clinical success<br>(cure + improvement) 
</td>
<td>
<br>65%<br>
</td>
<td>
<br>53%<br>
</td>
<td>
<br>77%<br>
</td>
<td>
<br>74%<br>
</td>
</tr>
<tr>
<td>
<br>Clinical cure <br>
</td>
<td>
<br>53%<br>
</td>
<td>
<br>44%<br>
</td>
<td>
<br>72%<br>
</td>
<td>
<br>64%<br>
</td>
</tr>
<tr class="Last">
<td>
<br>Clinical improvement <br>
</td>
<td>
<br>12%<br>
</td>
<td>
<br>9%<br>
</td>
<td>
<br>5%<br>
</td>
<td>
<br>10%<br>
</td>
</tr>
</tbody>
</table>* 95%Confidence interval around the success difference [-0.08, +0.32]. <br><span class="Sup">â€  </span>95%Confidence interval around the success difference 
[-0.1, +0.16].<br><br><br>In this trial and in a 
supporting maxillary puncture trial, 15 evaluable patients had 
non-beta-lactamaseâ€“producing <span class="Italics">Haemophilus influenzae 
</span>as the identified pathogen. Ten (10) of these 15 patients (67%) had their 
pathogen (non-beta-lactamase-producing <span class="Italics">Haemophilus 
influenzae</span>) eradicated. Eighteen (18) evaluable patients had <span class="Italics">Streptococcus pneumoniae </span>as the identified pathogen. 
Fifteen (15) of these 18 patients (83%) had their pathogen (<span class="Italics">Streptococcus pneumoniae</span>) eradicated.<br>Â <br><span class="Bold"><span class="Italics">Safety: </span></span>The incidence of 
drug-related gastrointestinal adverse events was statistically significantly 
higher in the control arm (an oral antimicrobial agent that contained a specific 
beta-lactamase inhibitor) versus the cefuroxime axetil arm (12%versus 1%, 
respectively; <span class="Italics">P</span>&lt;.001), particularly drug-related 
<span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (8%versus 1%, respectively;Â <span class="Italics">P </span>= 
.001).<br>Â <br><span class="Bold"><span class="Italics">Early <span class="product-label-link" type="condition" conceptid="440638" conceptname="Lyme disease">Lyme Disease</span>: 
</span></span>Two adequate and well-controlled studies were performed in 
patients with early <span class="product-label-link" type="condition" conceptid="440638" conceptname="Lyme disease">Lyme disease</span>. In these studies all patients had to present 
with physician-documented <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span> migrans, with or without systemic 
manifestations of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. Patients were randomized in a 1:1 ratio to a 20-day 
course of treatment with cefuroxime axetil 500 mg twice daily or doxycycline 100 
mg 3 times daily. Patients were assessed at 1 month posttreatment for success in 
treating early <span class="product-label-link" type="condition" conceptid="440638" conceptname="Lyme disease">Lyme disease</span> (Part I) and at 1 year posttreatment for success in 
preventing the progression to the sequelae of late <span class="product-label-link" type="condition" conceptid="440638" conceptname="Lyme disease">Lyme disease</span> (Part 
II).<br>Â <br>A total of 355 adult patients (181 treated with cefuroxime axetil 
and 174 treated with doxycycline) were enrolled in the 2 studies. In order to 
objectively validate the clinical diagnosis of early <span class="product-label-link" type="condition" conceptid="440638" conceptname="Lyme disease">Lyme disease</span> in these 
patients, 2 approaches were used:1) blinded expert reading of photographs, when 
available, of the pretreatment <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span> migrans <span class="product-label-link" type="condition" conceptid="4316083" conceptname="Skin lesion">skin lesion</span>; and 2) serologic 
confirmation (using enzyme-linked immunosorbent assay [ELISA] and immunoblot 
assay [â€œWesternâ€? blot]) of the presence of antibodies specific to <span class="Italics">Borrelia burgdorferi</span>, the etiologic agent of <span class="product-label-link" type="condition" conceptid="440638" conceptname="Lyme disease">Lyme disease</span>. 
By these procedures, it was possible to confirm the physician diagnosis of early 
<span class="product-label-link" type="condition" conceptid="440638" conceptname="Lyme disease">Lyme disease</span> in 281 (79%) of the 355 study patients. The efficacy data 
summarized below are specific to this â€œvalidatedâ€? patient subset, while the 
safety data summarized below reflect the entire patient population for the 2 
studies.<br>Â <br>Analysis of the submitted clinical data for evaluable patients 
in the â€œvalidatedâ€? patient subset yielded the following results:Â Â Â <br>Â  <br><a name="i17435479-ed81-4923-866d-65c1586932db"></a><table border="0" cellpadding="0" cellspacing="0">
<caption><span>Table 6. Clinical Effectiveness of Cefuroxime Axetil Tablets Compared 
to Doxycycline in the Treatment of Early <span class="product-label-link" type="condition" conceptid="440638" conceptname="Lyme disease">Lyme Disease</span> </span></caption>
<tbody class="Headless">
<tr class="First">
<td>
<br>Â <br>
</td>
<td>
<br>Â Â Â Â Â Â Â Â Â Â Â Â Â Â  Â Â Â  Â Â Â Â  Â Part I<br>Â Â Â Â  
Â  (1 Month Posttreatment)* </td>
<td>
<br>Â Â Â Â Â Â Â  Â Â Â Â  Â Â Â Â Â Â Part II<br>Â Â Â Â Â  Â (1 
Year Posttreatment)<span class="Sup">â€ </span>
</td>
</tr>
<tr>
<td>
<br>Cefuroxime Axetil<br>Â Â Â  Â (n = 125)</td>
<td>
<br>Â Doxycycline<br>Â Â  (n = 108)</td>
<td>
<br>Â Cefuroxime Axetil<br>Â Â Â Â  Â (n = 105<span class="Sup">â€¡</span>)</td>
<td>
<br>Â Doxycycline<br>Â Â  (n = 83<span class="Sup">â€¡</span>)</td>
</tr>
<tr>
<td>
<br>Satisfactory clinical outcome<span class="Sup">Â§</span><br>
</td>
<td>
<br>91%<br>
</td>
<td>
<br>93%<br>
</td>
<td>
<br>84%<br>
</td>
<td>
<br>87%<br>
</td>
</tr>
<tr>
<td>
<br>Â Â Â Clinical cure/success <br>
</td>
<td>
<br>72%<br>
</td>
<td>
<br>73%<br>
</td>
<td>
<br>73%<br>
</td>
<td>
<br>73%<br>
</td>
</tr>
<tr class="Last">
<td>
<br>Â Â Â Clinical improvement <br>
</td>
<td>
<br>19%<br>
</td>
<td>
<br>19%<br>
</td>
<td>
<br>10%<br>
</td>
<td>
<br>13%<br>
</td>
</tr>
</tbody>
</table>
<br>* 95%confidence interval around the satisfactory difference for Part I (-0.08, +0.05). <br><span class="Sup">â€  </span>95%confidence interval around the satisfactory differenceÂ  for Part II (-0.13, +0.07).<br><span class="Sup">â€¡Â  
</span>nâ€™s include patients assessed as unsatisfactory clinical outcomes 
(failure + recurrence)<br>Â  in Part I (cefuroxime axetil tablets - 11 [5 
failure, 6 recurrence]; doxycycline - 8 [6 failure, 2 recurrence]).<br><span class="Sup">Â§ </span>Satisfactory clinical outcome includes cure + improvement 
(Part I) and success + improvement (Part II).<br><br><br>Cefuroxime axetil and 
doxycycline were effective in prevention of the development of sequelae of late 
<span class="product-label-link" type="condition" conceptid="440638" conceptname="Lyme disease">Lyme disease</span>.<br>Â <br><span class="Bold"><span class="Italics">Safety: 
</span></span>Drug-related adverse events affecting the skin were reported 
significantly more frequently by patients treated with doxycycline than by 
patients treated with cefuroxime axetil (12%versus 3%, respectively; <span class="Italics">P </span>= .002), primarily reflecting the statistically 
significantly higher incidence of drug-related <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity reactions</span> in the 
doxycycline arm versus the cefuroxime axetil arm (9%versus 0%, respectively; 
<span class="Italics">P</span>&lt;.001). While the incidence of drug-related 
gastrointestinal adverse events was similar in the 2 treatment groups 
(cefuroxime axetil - 13%; doxycycline - 11%), the incidence of drug-related 
<span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> was statistically significantly higher in the cefuroxime axetil arm 
versus the doxycycline arm (11%versus 3%, respectively; <span class="Italics">P 
</span>= .005).<br>Â <br><span class="Bold"><span class="Italics">Secondary Bacterial 
<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> of <span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">Acute Bronchitis</span>: </span></span>Four randomized, controlled 
clinical studies were performed comparing 5 days versus 10 days of cefuroxime 
axetil for the treatment of patients with secondary <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infections</span> of 
<span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">acute bronchitis</span>. These studies enrolled a total of 1,253 patients (CAE-516 n = 
360; CAE-517 n = 177; CAEA4001 n = 362; CAEA4002 n = 354). The protocols for 
CAE-516 and CAE-517 were identical and compared cefuroxime axetil 250 mg twice 
daily for 5 days, cefuroxime axetil 250 mg twice daily for 10 days, and 
AUGMENTIN<span class="Sup">Â®</span> 500 mg 3 times daily for 10 days. These 2 
studies were conducted simultaneously. CAEA4001 and CAEA4002 compared cefuroxime 
axetil 250 mg twice daily for 5 days, cefuroxime axetil 250 mg twice daily for 
10 days, and CECLOR<span class="Sup">Â®</span> 250 mg 3 times daily for 10 days. 
They were otherwise identical to CAE-516 and CAE-517 and were conducted over the 
following 2 years. Patients were required to have polymorphonuclear cells 
present on the Gram stain of their screening <span class="product-label-link" type="condition" conceptid="4102774" conceptname="Productive cough">sputum</span> specimen, but isolation of a 
bacterial pathogen from the <span class="product-label-link" type="condition" conceptid="4102774" conceptname="Productive cough">sputum</span> culture was not required for inclusion. The 
following table demonstrates the results of the clinical outcome analysis of the 
pooled studies CAE-516/CAE-517 and CAEA4001/CAEA4002, respectively:<br>Â <br><a name="i0aec4611-eeb6-4cc3-8d66-9b0cfe19e353"></a><table border="0" cellpadding="0" cellspacing="0">
<caption><span>Table 7.Â  Clinical Effectiveness of Cefuroxime Axetil Tablets 250 mg 
Twice Daily in Secondary <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">Bacterial Infections</span> of <span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">Acute Bronchitis</span>: Comparison of 
5 Versus 10 Daysâ€™ Treatment Duration </span></caption>
<tbody class="Headless">
<tr class="First">
<td>
<br>Â <br>
</td>
<td>
<br>CAE-516 and<br>CAE-517*</td>
<td>
<br>CAEA4001 and<br>CAEA4002<span class="Sup">â€ </span>
</td>
</tr>
<tr>
<td>
<br>5 day<br>(n = 127)</td>
<td>
<br>Â  10 day<br>(n = 139)</td>
<td>
<br>Â  5 day<br>(n = 173)</td>
<td>
<br>Â  10 day<br>(n = 192)</td>
</tr>
<tr>
<td>
<br>Clinical success<br>(cure + 
improvement)</td>
<td>
<br>80%<br>
</td>
<td>
<br>87%<br>
</td>
<td>
<br>84%<br>
</td>
<td>
<br>82%<br>
</td>
</tr>
<tr>
<td>
<br>Clinical cure <br>
</td>
<td>
<br>61%<br>
</td>
<td>
<br>70%<br>
</td>
<td>
<br>73%<br>
</td>
<td>
<br>72%<br>
</td>
</tr>
<tr class="Last">
<td>
<br>Clinical improvement <br>
</td>
<td>
<br>19%<br>
</td>
<td>
<br>17%<br>
</td>
<td>
<br>11%<br>
</td>
<td>
<br>10%<br>
</td>
</tr>
</tbody>
</table>* 95%Confidence interval around the success difference<br>[-0.164, +0.029]. 
<br><span class="Sup">â€  </span>95%Confidence interval around the success 
difference<br>[-0.061, +0.103].<br><br><br><br>The response rates for 
patients who were both clinically and bacteriologically evaluable were 
consistent with those reported for the clinically evaluable 
patients.<br>Â <br><span class="Bold"><span class="Italics">Safety: </span></span>In 
these clinical trials, 399 patients were treated with cefuroxime axetil for 5 
days and 402 patients with cefuroxime axetil for 10 days. No difference in the 
occurrence of adverse events was observed between the 2 regimens.<a href="http://"></a>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="section-13"></a><p></p>
<h1>REFERENCES</h1>
<ol>
<li>National Committee for Clinical Laboratory Standards. <span class="Italics">Methods for Dilution Antimicrobial Susceptibility Tests for 
Bacteria that Grow Aerobically</span>. 3rd ed. Approved Standard NCCLS Document 
M7-A3, Vol. 13, No. 25. Villanova, Pa: NCCLS; 1993. </li>
<li>National Committee for Clinical Laboratory Standards. <span class="Italics">Performance Standards for Antimicrobial Disk Susceptibility 
Tests</span>. 4th ed. Approved Standard NCCLS Document M2-A4, Vol. 10, No. 7. 
Villanova, Pa: NCCLS; 1990.Â Â </li>
</ol>
<br>AUGMENTIN<span class="Sup">Â®</span> and 
CECLOR<span class="Sup">Â®</span> are registered trademarks of 
GlaxoSmithKline.<br>CLINITEST and CLINISTIX are registered trademarks of Ames 
Division, Miles Laboratories, Inc.Â <br><br>Manufactured for:<br><span class="Bold">Aurobindo Pharma USA, Inc.</span><br>2400 Route 130 North<br>Dayton, 
NJ 08810Â <br>Â <br>Manufactured by:<br><span class="Bold">Aurobindo Pharma 
Limited</span><br>Chitkul (v)-502 307, A.P., India<br><br><br><br><span class="Bold">Relabeling and Repackaging by:<br></span>Physicians Total Care, Inc.<br>Tulsa, OKÂ Â Â Â Â Â  74146<br>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-14"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL</h1>
<p class="First"><span class="Bold">Cefuroxime Axetil Tablets, USP 250 mg <br></span></p>
<p><img alt="image of 250 mg package label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=61d3f51b-a8ed-4be5-849c-4bf653538d3e&amp;name=4987.jpg"><br><span class="Bold"></span></p>
<p><span class="Bold">Cefuroxime Axetil Tablets, USP 500 mg</span></p>
<p><img alt="image of 500 mg package label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=61d3f51b-a8ed-4be5-849c-4bf653538d3e&amp;name=5022.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CEFUROXIME AXETILÂ 		
					</strong><br><span class="contentTableReg">cefuroxime axetil tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-4987(NDC:65862-034)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>CEFUROXIME AXETIL</strong> (CEFUROXIME) </td>
<td class="formItem">CEFUROXIME AXETIL</td>
<td class="formItem">250Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM LAURYL SULFATE</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">white (white to off-white) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL (capsule-shaped) </td>
<td class="formLabel">Size</td>
<td class="formItem">16mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">A33</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-4987-0</td>
<td class="formItem">20  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:54868-4987-1</td>
<td class="formItem">30  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA065308</td>
<td class="formItem">01/30/2004</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CEFUROXIME AXETILÂ 		
					</strong><br><span class="contentTableReg">cefuroxime axetil tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-5022(NDC:65862-035)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>CEFUROXIME AXETIL</strong> (CEFUROXIME) </td>
<td class="formItem">CEFUROXIME AXETIL</td>
<td class="formItem">500Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM LAURYL SULFATE</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">white (white to off-white) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL (capsule-shaped) </td>
<td class="formLabel">Size</td>
<td class="formItem">20mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">A34</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-5022-0</td>
<td class="formItem">30  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:54868-5022-1</td>
<td class="formItem">20  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:54868-5022-2</td>
<td class="formItem">15  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">4</th>
<td class="formItem">NDC:54868-5022-3</td>
<td class="formItem">60  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA065308</td>
<td class="formItem">03/17/2004</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Physicians Total Care, Inc.
							(194123980)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Physicians Total Care, Inc.</td>
<td class="formItem"></td>
<td class="formItem">194123980</td>
<td class="formItem">relabel, repack</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 12/2010<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>2f5eb9a3-64c5-4790-89d0-7a6c98e5f37b</div>
<div>Set id: 61d3f51b-a8ed-4be5-849c-4bf653538d3e</div>
<div>Version: 1</div>
<div>Effective Time: 20101209</div>
</div>
</div>Â <div class="DistributorName">Physicians Total Care, Inc.</div></p>
</body></html>
